Table 1.
Chemically synthesized lanthipeptides, analogues and mimics, with corresponding yields
| Lanthipeptide, analogue or mimic (lab-scale synthesis) | Amount obtained (mg) | Product yield (%) | No. of steps | Approx. average yield per step (%) | References |
|---|---|---|---|---|---|
| Nisin | ND | 0.003a | ND | 70 | [56] |
| Lactocin S | 1.5 | 10 | 71 | 97 | [57] |
| Lacticin 3147 | 4.8 | 1.0–1.4 | >50 | >95 | [22] |
| Lacticin 481 | 2.0 | 1.3 | 52 | 92 | [35] |
| Epilancin 15X | 2.0 | 1.6 | 59 | 93 | [58] |
| DAP-substituted ring A of lactocin S | 1.5 | 2.5 | >71 | 93 | [44] |
| Norleucine substituted lactocin S | 0.8 | 0.8 | >70 | ND | [59] |
| Nle, DAP-substituted lactocin S | 1.0 | 1.8 | >70 | ND | [59] |
| N-terminal oxazole lactocin S | 0.33 | 0.3 | >70 | ND | [59] |
| Alkene substituted lacticin 3147 Ltnβ | 1.8 | 0.5 | 53 | 76 | [40] |
| Oxygen substituted lacticin 3147 | 1.1 | 0.3 | 53 | 90 | [41] |
| Bis(desmethyl)lacticin 3147 | 1.0 | 1.3 | >50 | 84 | [43] |
| LL- diastereomers of lacticin 481 | 1.9 | 1.3 | >53 | 92 | [35] |
| N-truncated variant of Epilancin 15X | 1.2 | 1.9 | 45 | 92 | [58] |
ND data not described
acrude product yield before HPLC purification, obtained by calculating the overall yield of the five individually synthesized ring fragments and then the yield of putting these fragments together as performed by Shiba [56]